Pathways to Progress: Outlining Key Steps to Diagnosis and Evolving Therapeutic Approaches in CIDP

Program Description

Despite recent advancements in chronic inflammatory demyelinating polyneuropathy (CIDP), significant challenges persist in its accurate diagnosis and optimal treatment. Throughout this program, Drs. Nicholas J. Silvestri, Christyn Edmundson, and Kelly G. Gwathmey will share their expertise, as they guide you through common electrodiagnostic and management pitfalls, outlining evidence-based approaches and drawing from their clinical experience with this rare disease. Through a close examination of guideline recommendations, our faculty will demonstrate strategies for the early recognition, accurate diagnosis, and contemporary treatment of CIDP. They will also explore treatment gaps, highlight individual patient needs, and provide crucial insights into the latest research on emerging mechanisms of action, such as complement and FcRn inhibitors, and newly approved delivery methods like facilitated subcutaneous immunoglobulins. This activity provides an opportunity both to stay updated on the most recent data of potentially transformative agents and learn how to improve patient outcomes using today's therapeutic armamentarium.

Target Audience

This activity is intended for neurologists, neuromuscular specialists, and advanced practice providers, including nurse practitioners and physician assistants, who care for patients with suspected or confirmed CIDP in neurology settings.

Learning Objectives

Upon completion of the educational activity, participants should be able to:

  • Formulate streamlined, evidence-based strategies to accurately diagnose CIPD that consider all possible symptoms and atypical variants, as well as clinical tests and current diagnostic criteria to ensure patients are not misdiagnosed 
  • Examine the variable risks and benefits of traditional approaches for first-line and refractory treatments to more effectively individualize therapeutic regimens 
  • Distinguish the mechanisms of action and phase 2/3 data for emerging broad spectrum and targeted therapies in CIDP to assess their potential future role in clinical practice
Course summary
Available credit: 
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Attendance
Course opens: 
Course expires: 
   Nicholas J. Silvestri, MD, FAAN (Course Director)
   Professor of Neurology
   Associate Dean for Student and Academic Affairs
   University at Buffalo Jacobs School of Medicine and Biomedical Sciences
   Buffalo, NY
   Christyn Edmundson, MD
   Director of Neuromuscular Medicine
   Swedish Neuroscience Institute
   Seattle, WA
   Kelly Graham Gwathmey, MD
   Associate Professor of Neurology
   Neuromuscular Division Chair
   Department of Neurology
   Virginia Commonwealth University
   Richmond, VA

This activity is jointly provided by Partners for Advancing Clinical Education (PACE) and Efficient LLC.


Joint Accreditation Statement


In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Efficient LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

PACE designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
A Certificate of Participation will be given upon completion of the enduring activity enabling participants to register their credit with the appropriate licensing boards or associations.

Faculty and Disclosure of Conflicts of Interest

PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

Dr. Silvestri reported the following financial relationships:
Consulting Fees: Alexion, Argenx, Inhibrx, Immunovant, Janssen, UCB
Other: Regeneron
Dr. Edmundson reported the following financial relationships:
Consulting Fees: Alexion, Alnylam, Argenx, UCB

Dr. Gwathmey reported the following financial relationships:
Consulting Fees: Alexion, Argenx, UCB

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The Efficient LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Commercial Support

This activity is supported by an educational grant from Sanofi. 

Available Credit

  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Attendance


Please login or register to take this course.